Natera, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Natera (NTRA) has started a randomized melanoma study with NYU Langone, using its Signatera test to guide therapy based on minimal residual disease after initial treatment. The trial's primary goal is to measure progression-free survival.
Natera (NTRA) stock fell 6.0% after hitting a 52-week high, despite positive news. Citi raised its price target to $480, and Natera announced new data and a trial. Insider selling and high valuation contributed to the decline. The broader market advanced, indicating the move was company-specific.
Analysts updated ratings and price targets for several companies. Nike (NKE) was downgraded to sell with a target reduced to $27.50. AMD (AMD) was upgraded with a target raised to $705. Other notable changes include Intel (INTC) raised to $114, Meta (META) to $1,000, and Valero (VLO) to $441.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning NTRA (Natera, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 1 bearish.
Recent NTRA coverage spans financial news, insider activity and market movers.
In the last 30 days, NTRA insiders filed 58 SEC Form 4 transactions — no purchases and 58 sales ($63.2M). The most active reporter was Rabinowitz Matthew, EXECUTIVE CHAIRMAN, with 35 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The trial start could lift Natera's stock if early data are positive, but uncertainty remains until results.
The stock is likely to face continued downside as profit‑taking and insider selling outweigh recent positive catalysts.
Higher target may support upside.
The insider sale may cause modest downward pressure on Natera's stock as investors digest the reduction in insider ownership.
The insider sale may signal modest downside pressure.
AlphAI scores every news story that mentions NTRA with an AI model for sentiment and relevance, and aggregates insider trades from Natera, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Natera (NTRA) has started a randomized melanoma study with NYU Langone, using its Signatera test to guide therapy based on minimal residual disease after initial treatment. The trial's primary goal is to measure progression-free survival.
1 min readNatera (NTRA) stock fell 6.0% after hitting a 52-week high, despite positive news. Citi raised its price target to $480, and Natera announced new data and a trial. Insider selling and high valuation contributed to the decline. The broader market advanced, indicating the move was company-specific.
2 min readAnalysts updated ratings and price targets for several companies. Nike (NKE) was downgraded to sell with a target reduced to $27.50. AMD (AMD) was upgraded with a target raised to $705. Other notable changes include Intel (INTC) raised to $114, Meta (META) to $1,000, and Valero (VLO) to $441.
2 min readChapman Steven Leonard (CEO AND PRESIDENT) sold 1,273 shares of Natera, Inc. (NTRA) at $413.31 ($0.53M total) on 2026-10-01 under a Rule 10b5-1 trading plan.
1 min readMoshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 3,000 shares of Natera, Inc. (NTRA) at an average of $414.22 ($411.62–$415.07, $1.24M total) across 3 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
1 min readNatera officer Solomon Moshkevich proposed selling 3,000 shares worth $1.24M, with a planned sale date of October 1, 2026. The filing also lists five prior sales by Moshkevich between July and September 2026, with 144.1M shares outstanding. According to the company, the sale is subject to Rule 144 regulations.
1 min readOn CNBC’s ‘Final Trades,’ Rob Sechan picked Hewlett Packard Enterprise (HPE) due to its better-than-expected Q3 results and raised guidance. Kevin Simpson chose Natera (NTRA), citing an RBC analyst’s price target increase. Stephen Weiss recommended UnitedHealth Group (UNH), which reports Q3 earnings on Oct. 13. HPE shares fell 0.9%, NTRA rose 0.9%, and UNH gained 0.4% on Friday.
2 min readJonathan Sheena, a director of Natera (NTRA), saw trusts associated with him sell $7.0m in NTRA stock on September 23, 2026. The stock has gained 153% over the past year, trading near its 52-week high. Natera reported Q2 2026 revenue of $753m, exceeding estimates, and raised its full-year guidance. RBC Capital increased its price target to $460, while Rothschild Redburn initiated coverage with a Buy rating and a $385 target.
2 min readSheena Jonathan sold 18,064 indirectly-held shares of Natera, Inc. (NTRA) at an average of $388.01 ($385.10–$390.52, $7.01M total) across 12 trades on 2026-09-23 under a Rule 10b5-1 trading plan.
1 min readNatera Inc (NTRA) options show a 12.6:1 put/call ratio, with 2,934 puts vs. 233 calls, near its 52-week high of $415.75. The largest put strikes are $400, $360, and $320, with low open interest suggesting new positions. Insiders sold shares in 2024, adding to the bearish sentiment.
2 min read
